SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: StockDung6/20/2009 4:43:58 PM
   of 5582
 
Was Loss of Smell from Zicam Nasal Products Really a "Big Surprise"?

lansing.injuryboard.com

David Mittleman Attorney

(877) 245-6841 Ext 430
June 20, 2009 11:55 AM

Matrixx, the manufacturer of Zicam cold medicines, stated that it was a “complete surprise” when they received a warning letter from the FDA last Tuesday, telling them to stop selling their intranasal products because of the harmful effects they had on consumers’ sense of smell. However, new information has arisen that the company already knew that their products were dangerous. In fact, in a routine investigation of Matrixx back in May, the FDA discovered that the company had received 800 consumer complaints that users were losing their sense of smell from using nasal gel and nasal swab products, which the company did not report to the FDA.

In a conference call on Thursday, the acting president and chief operating officer of Matrixx, said he was advised by his legal council that he was not required to turn over the 800 complaints because they did not fit with a 2007 FDA regulation requiring companies to turn over reports of serious side effects from non-prescription, homeopathic medicines. He also added that the recall of the products will cost the company $10 million and will ultimately “shrink the company”.

Matrixx must seek FDA approval if they want to continue marketing their nasal products. However, Matrixx acting president and chief operating officer said that would take too long and would be “highly expensive”. Instead, the company is currently seeking a meeting with the FDA, to attempt to get them to reverse their decision using several of their own studies that allegedly show that the nasal medicines did not result in loss of smell.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext